Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Willekens

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Gut Microbes|September 7, 2020
Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengtheningThomas Hueso, Kenneth Ekpe, Camille Mayeur, et al.
Leukemia|April 26, 2023
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in miceChristophe Willekens, Lucie Laplane, Tracy Dagher, et al.
Nature Medicine|July 18, 2018
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenibLynn Quek, Muriel D David, Alison Kennedy, et al.
Journal of Proteome Research|October 1, 2024
Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19Jean-Marie Michot, Vito Dozio, Julien Rohmer, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
Nature Cancer|February 5, 2022
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohortLaurence Albiges, Stéphanie Foulon, Arnaud Bayle, et al.
The Journal of Clinical Investigation|November 15, 2024
CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemiaPaul Deschamps, Margaux Wacheux, Axel Gosseye, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Cell Death & Disease|March 12, 2021
Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkersFrançois-Xavier Danlos, Claudia Grajeda-Iglesias, Sylvère Durand, et al.
Cell|August 19, 2020
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19Aymeric Silvin, Nicolas Chapuis, Garett Dunsmore, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Gut Microbes|September 7, 2020
Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengtheningThomas Hueso, Kenneth Ekpe, Camille Mayeur, et al.
Leukemia|April 26, 2023
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in miceChristophe Willekens, Lucie Laplane, Tracy Dagher, et al.
Nature Medicine|July 18, 2018
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenibLynn Quek, Muriel D David, Alison Kennedy, et al.
Journal of Proteome Research|October 1, 2024
Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19Jean-Marie Michot, Vito Dozio, Julien Rohmer, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
Nature Cancer|February 5, 2022
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohortLaurence Albiges, Stéphanie Foulon, Arnaud Bayle, et al.
The Journal of Clinical Investigation|November 15, 2024
CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemiaPaul Deschamps, Margaux Wacheux, Axel Gosseye, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Cell Death & Disease|March 12, 2021
Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkersFrançois-Xavier Danlos, Claudia Grajeda-Iglesias, Sylvère Durand, et al.
Cell|August 19, 2020
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19Aymeric Silvin, Nicolas Chapuis, Garett Dunsmore, et al.
Pageof 5